Literature DB >> 9884270

Histologic grading of acute allograft rejection in pancreas needle biopsy: correlation to serum enzymes, glycemia, and response to immunosuppressive treatment.

J C Papadimitriou1, C B Drachenberg, A Wiland, D K Klassen, J Fink, M R Weir, C Cangro, E J Schweitzer, S T Bartlett.   

Abstract

BACKGROUND: Allograft rejection continues to be the most common cause of graft failure in technically successful pancreas transplants. Early diagnosis and treatment of rejection is essential for long-term graft survival. Pancreas graft biopsies are now used routinely for the diagnosis of acute allograft rejection. The correlation between clinical evidence of graft dysfunction (increased serum enzymes and glucose), severity of acute rejection on biopsy (rejection grade), and response to treatment has not been previously studied.
METHODS: A total of 151 pancreas transplant needle biopsy specimens from 57 patients were evaluated. Statistical correlation was done between the histologic rejection grade (O-V) and the peak level of enzymes in serum, glycemia, type of antirejection treatment instituted, and response to treatment. Differentiation between grades was also evaluated statistically.
RESULTS: Response to antirejection treatment was 25%, 40%, 88%, 78%, 50%, and 17% for grades O-V, respectively. The response for grades II and III was better than for grades 0-I and IV-V (P=0.0003 and 0.0008, respectively). The response to corticosteroids alone was 36%, 86%, 68%, and 0% for grades I, II, III, and IV, respectively. The response to antilymphocyte regimen was 50%, 89%, 85%, 71%, and 17% for grades I, II, III, IV, and V, respectively. Overall correlation between the mean levels of enzymes and rejection grade was seen; the increase of lipase was statistically significant (r=0.24, P=0.012). Amylase and lipase correlated very well with each other (r=0.84, P=0.0001). No correlation was found in the mean values of blood glucose with the serum enzyme increase and with severity of rejection. Hyperglycemia was present in 12 patients; this abnormality in patients with grades II-IV responded promptly to treatment, whereas in patients with grade V, hyperglycemia persisted despite antirejection treatment. Other causes of increased enzymes were found in patients with biopsy specimens showing no rejection (grades 0 and I, 43% and 31%, respectively).
CONCLUSIONS: Increased serum enzymes, particularly lipase, correlate with the grade of acute rejection, but their lack of specificity precludes their use as sole markers of acute rejection. Glucose levels are not a sensitive marker for acute rejection. Rejection grades II and III are the most responsive to treatment, and a significant proportion of these cases respond to treatment with corticosteroids only. The higher rejection grades (IV and V) require treatment with antilymphocytic regimens, and their overall response to treatment is moderate to poor, respectively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9884270     DOI: 10.1097/00007890-199812270-00030

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Pancreas transplantation: lessons learned from a decade of experience at Wake Forest Baptist Medical Center.

Authors:  Jeffrey Rogers; Alan C Farney; Samer Al-Geizawi; Samy S Iskandar; William Doares; Michael D Gautreaux; Lois Hart; Scott Kaczmorski; Amber Reeves-Daniel; Stephanie Winfrey; Mythili Ghanta; Patricia L Adams; Robert J Stratta
Journal:  Rev Diabet Stud       Date:  2011-05-10

Review 2.  Lessons learned from more than 1,000 pancreas transplants at a single institution.

Authors:  D E Sutherland; R W Gruessner; D L Dunn; A J Matas; A Humar; R Kandaswamy; S M Mauer; W R Kennedy; F C Goetz; R P Robertson; A C Gruessner; J S Najarian
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

Review 3.  Pancreatic and islet transplantation.

Authors:  L Rosenberg
Journal:  Curr Gastroenterol Rep       Date:  2000-04

4.  Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.

Authors:  Tadahiro Uemura; Varun Ramprasad; Kazuhide Matsushima; Hiroko Shike; Tracy Valania; Osun Kwon; Nasrollah Ghahramani; Riaz Shah; Umar Farooq; Akhtar Khan; Zakiyah Kadry
Journal:  Transplantation       Date:  2011-09-27       Impact factor: 4.939

5.  Pancreas transplantation: The Wake Forest experience in the new millennium.

Authors:  Jeffrey Rogers; Alan C Farney; Giuseppe Orlando; Samy S Iskandar; William Doares; Michael D Gautreaux; Scott Kaczmorski; Amber Reeves-Daniel; Amudha Palanisamy; Robert J Stratta
Journal:  World J Diabetes       Date:  2014-12-15

6.  A pilot study of gene expression-based categorization of pancreas transplant biopsies.

Authors:  Fu L Luan; Fabian Trillsch; Anna Henger; Felix Eichinger; Silas Norman; Henry Appelman; Matthias Kretzler
Journal:  Transplantation       Date:  2009-01-27       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.